Precipio, a specialty cancer diagnostics company, will hold its Q3 2026 shareholder update call on November 10, 2026, at 5:00 PM ET. The call will cover the company's recent revenue growth, particularly in its Products Division, and provide insights into its strategic vision for 2027 and beyond. A live Q&A session will follow the presentation, allowing investors to engage directly with management. The company aims to improve cancer diagnosis accuracy and reduce healthcare costs through innovative diagnostic products and services.
Precipio's Q3 2026 shareholder update call is scheduled for November 10, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 03:21 WIB: out of 150 priced US health stocks, 103 rose and 46 fell. Notable movers include TDOC (Teladoc Health Inc) at USD 7.55 with a 1-day change of +17.05% and a typical hold time on Pluang of 39 days, SLS (SELLAS Life Sciences Group Inc.) at USD 10.38 down 14.71% with a 7-day hold, and CLPT (ClearPoint Neuro Inc) at USD 10.57 up 9.08% with balanced order activity and an 11-day hold time.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
Vivid Seats Inc., a leading online ticket marketplace, will announce its financial results for the third quarter of 2026 on November 9, 2026, before the U.S. stock market opens. The company will host a webcast at 8:30 a.m. ET to discuss the results. ...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
